Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0022 in KRAS G12D-mutant advanced solid tumors
NL-OMON58770Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD0022 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Incidence of dose-limiting toxicities and 3 more. Started Aug 2025; status: completed.
02
Drugs
AZD0022
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON58770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58770.